FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094337514> ?p ?o ?g. }

• W3094337514 endingPage "28" @default.
• W3094337514 startingPage "20" @default.
• W3094337514 abstract "A high density of CD8+ tumor infiltrating lymphocytes (TILs) is associated with improved survival in multiple cancers, but its prognostic role in prostate cancer remains controversial. The aim of our study was to evaluate the prognostic value of CD8+ TILs in prostate cancer patients undergoing radical prostatectomy (RP). We hypothesized that elevated density of CD8+ TILs in the RP specimen would correlate with improved clinical outcomes. This information may be helpful for future immunotherapy clinical trial design and treatment selection.Tumor microarrays constructed from 230 patients with localized prostate cancers who underwent RP from 2006 to 2012 at Roswell Park Comprehensive Cancer Center were analyzed retrospectively using immunohistochemistry. CD8+ cell density was evaluated using a computerized scoring system. The cohorts were separated by CD8+ TIL density at the 25th percentile (i.e., low <quartile 1 and high ≥quartile 1). The quartile 1 threshold was chosen through a minimal p value approach based on overall survival with correction of significance to adjust for multiple testing. Clinical outcomes were compared in the high versus low CD8+ TIL density groups.One hundred and forty-nine (65%) patients had high risk diseases (Gleason >7 or pT3/4). The median follow-up time was 8.4 years. High CD8+ TIL density was associated with improved 5-year overall survival (98% vs. 91%, p = .01) and prostate cancer-specific survival (99% vs. 95%, p = .04) compared with patients with low CD8+ TIL density. There was a trend toward higher 5-year biochemical recurrence-free survival and metastasis-free survival in the cohort of patients with high CD8+ TIL density (52% vs. 38% and 86% vs. 73%, respectively), although the difference did not reach statistical significance (p = .18 and p = .05, respectively). In a multivariate analysis high CD8+ TIL density was an independent favorable prognostic factor for overall survival (hazards ratio = 0.38; 95% confidence interval: 0.17-0.87; p = .02). In contrast to the prognostic value of CD8+ TIL density, the CD8+ cell density in the matched normal prostate tissue was not associated with any clinical outcomes.Intratumoral CD8+ T-cell infiltration in the RP specimen is independently associated with improved survival after RP in this high-risk prostate cancer cohort. Pre-RP immunomodulation that promotes intratumoral CD8+ cytotoxic T-cell infiltration may be beneficial for this population." @default.
• W3094337514 created "2020-10-29" @default.
• W3094337514 creator A5011054139 @default.
• W3094337514 creator A5040346750 @default.
• W3094337514 creator A5041497751 @default.
• W3094337514 creator A5045228500 @default.
• W3094337514 creator A5057788524 @default.
• W3094337514 creator A5061950952 @default.
• W3094337514 creator A5074919849 @default.
• W3094337514 creator A5089256383 @default.
• W3094337514 date "2020-10-21" @default.
• W3094337514 modified "2023-10-17" @default.
• W3094337514 title "High intratumoral CD8 ⁺ T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy" @default.
• W3094337514 cites W1500124513 @default.
• W3094337514 cites W1569975580 @default.
• W3094337514 cites W1599507531 @default.
• W3094337514 cites W1868820697 @default.
• W3094337514 cites W1979811833 @default.
• W3094337514 cites W1982757300 @default.
• W3094337514 cites W2009423208 @default.
• W3094337514 cites W2009719437 @default.
• W3094337514 cites W2039123767 @default.
• W3094337514 cites W2042699075 @default.
• W3094337514 cites W2060469376 @default.
• W3094337514 cites W2062135418 @default.
• W3094337514 cites W2064164513 @default.
• W3094337514 cites W2085776136 @default.
• W3094337514 cites W2092230683 @default.
• W3094337514 cites W2093403667 @default.
• W3094337514 cites W2095724207 @default.
• W3094337514 cites W2096151993 @default.
• W3094337514 cites W210579078 @default.
• W3094337514 cites W2133123802 @default.
• W3094337514 cites W2141269240 @default.
• W3094337514 cites W2142300779 @default.
• W3094337514 cites W2143445035 @default.
• W3094337514 cites W2145449065 @default.
• W3094337514 cites W2152118650 @default.
• W3094337514 cites W2160537718 @default.
• W3094337514 cites W2160834915 @default.
• W3094337514 cites W2294356527 @default.
• W3094337514 cites W2349584574 @default.
• W3094337514 cites W2523928754 @default.
• W3094337514 cites W2531934133 @default.
• W3094337514 cites W2560322684 @default.
• W3094337514 cites W2560367415 @default.
• W3094337514 cites W2603526557 @default.
• W3094337514 cites W2654384024 @default.
• W3094337514 cites W2769704777 @default.
• W3094337514 cites W2896846797 @default.
• W3094337514 cites W2900162281 @default.
• W3094337514 cites W2922242701 @default.
• W3094337514 cites W2945522282 @default.
• W3094337514 cites W2990771207 @default.
• W3094337514 cites W3015726774 @default.
• W3094337514 doi "https://doi.org/10.1002/pros.24068" @default.
• W3094337514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33085799" @default.
• W3094337514 hasPublicationYear "2020" @default.
• W3094337514 type Work @default.
• W3094337514 sameAs 3094337514 @default.
• W3094337514 citedByCount "38" @default.
• W3094337514 countsByYear W30943375142021 @default.
• W3094337514 countsByYear W30943375142022 @default.
• W3094337514 countsByYear W30943375142023 @default.
• W3094337514 crossrefType "journal-article" @default.
• W3094337514 hasAuthorship W3094337514A5011054139 @default.
• W3094337514 hasAuthorship W3094337514A5040346750 @default.
• W3094337514 hasAuthorship W3094337514A5041497751 @default.
• W3094337514 hasAuthorship W3094337514A5045228500 @default.
• W3094337514 hasAuthorship W3094337514A5057788524 @default.
• W3094337514 hasAuthorship W3094337514A5061950952 @default.
• W3094337514 hasAuthorship W3094337514A5074919849 @default.
• W3094337514 hasAuthorship W3094337514A5089256383 @default.
• W3094337514 hasConcept C121608353 @default.
• W3094337514 hasConcept C126322002 @default.
• W3094337514 hasConcept C126894567 @default.
• W3094337514 hasConcept C143998085 @default.
• W3094337514 hasConcept C167672396 @default.
• W3094337514 hasConcept C203014093 @default.
• W3094337514 hasConcept C2776235491 @default.
• W3094337514 hasConcept C2777701055 @default.
• W3094337514 hasConcept C2778326572 @default.
• W3094337514 hasConcept C2779466945 @default.
• W3094337514 hasConcept C2780192828 @default.
• W3094337514 hasConcept C44249647 @default.
• W3094337514 hasConcept C68443243 @default.
• W3094337514 hasConcept C71924100 @default.
• W3094337514 hasConcept C8891405 @default.
• W3094337514 hasConceptScore W3094337514C121608353 @default.
• W3094337514 hasConceptScore W3094337514C126322002 @default.
• W3094337514 hasConceptScore W3094337514C126894567 @default.
• W3094337514 hasConceptScore W3094337514C143998085 @default.
• W3094337514 hasConceptScore W3094337514C167672396 @default.
• W3094337514 hasConceptScore W3094337514C203014093 @default.
• W3094337514 hasConceptScore W3094337514C2776235491 @default.
• W3094337514 hasConceptScore W3094337514C2777701055 @default.
• W3094337514 hasConceptScore W3094337514C2778326572 @default.
• W3094337514 hasConceptScore W3094337514C2779466945 @default.

• next